Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Genetics Closes Acquisition of Coelacanth

NEW YORK, July 13 – Lexicon Genetics of The Woodlands, Texas, has closed the deal to acquire Coelacanth in a stock transaction valued at $32 million.

Under the terms of the final merger agreement announced Thursday, Lexicon will distribute 2,918,991 shares of common stock to Coelacanth stockholders. The deal is based on Lexicon’s average closing price of $10.9625 per share during the 30 days ending three days prior to the effective date of the merger.

Coelacanth uses proprietary chemistry technologies to discover new chemical entities for drug development. The newly acquired company will make up the core of Lexicon’s new division, Lexicon Pharmaceuticals, which will be based in Princeton, N.J. 

Lexicon Pharmaceuticals will combine Lexicon's defined targets from the human genome with Coelacanth chemistry technologies to discover new drugs. 

Established in 1996, Coelacanth has screening libraries and an industrialized medicinal chemistry platform to create drug development candidates.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.